Edition:
United Kingdom

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

5.96USD
18 Jan 2019
Change (% chg)

$-1.74 (-22.60%)
Prev Close
$7.70
Open
$5.80
Day's High
$6.30
Day's Low
$5.29
Volume
714,362
Avg. Vol
182,603
52-wk High
$13.97
52-wk Low
$5.29

Chart for

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of... (more)

Overall

Beta: 0.15
Market Cap(Mil.): $1,239.53
Shares Outstanding(Mil.): 105.58
Dividend: --
Yield (%): --

Financials

  LXRX.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -1.33 -- --
ROI: -42.10 8.99 14.48
ROE: -85.52 10.13 15.99

FDA advisory panel split over Sanofi-Lexicon diabetes drug

An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

18 Jan 2019

UPDATE 2-FDA advisory panel split over Sanofi-Lexicon diabetes drug

Jan 17 An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

17 Jan 2019

FDA advisory panel split over Sanofi-Lexicon diabetes drug

Jan 17 Independent experts on an FDA advisory panel were equally split when voting on whether to approve an oral treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

17 Jan 2019

Earnings vs. Estimates